<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In most developed countries, malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> account for 10--15% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> occurring among children aged 0--14 years </plain></SENT>
<SENT sid="1" pm="."><plain>The present study estimates survival after a diagnosis of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in childhood, based on the EUROCARE II database which includes 34 population-based <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries from 17 European countries </plain></SENT>
<SENT sid="2" pm="."><plain>The survival pattern of children with malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> diagnosed in 1985--1989 is reported, as well as the time trends since 1978 </plain></SENT>
<SENT sid="3" pm="."><plain>The analyses focus on <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, 1696 cases) and on non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL, 2255 cases including Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and unspecified <z:hpo ids='HP_0002665'>lymphomas</z:hpo>) </plain></SENT>
<SENT sid="4" pm="."><plain>For <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, the European weighted average 5-year survival rate was 93% (95% confidence interval (CI) 82--98) in 1985--1989 </plain></SENT>
<SENT sid="5" pm="."><plain>The survival rates were not affected by either age or gender </plain></SENT>
<SENT sid="6" pm="."><plain>5-year survival rates ranged from 68% (95% CI 34--90) in Estonia to 96% (95% CI 92--98) in Germany and 100% (95% CI 57--100) in Slovenia </plain></SENT>
<SENT sid="7" pm="."><plain>Multivariate analyses for the time period 1978--1989 gave little suggestion of an improvement in survival over the later time periods of diagnosis </plain></SENT>
<SENT sid="8" pm="."><plain>For NHL, the European weighted average 5-year survival rate was 74% (95% CI 67--80) in 1985--1989 </plain></SENT>
<SENT sid="9" pm="."><plain>Gender did not influence the survival rate </plain></SENT>
<SENT sid="10" pm="."><plain>Children in the age group 0--4 years had a poorer prognosis compared with older cases (5-year rate: 66% versus 77% in the pool) </plain></SENT>
<SENT sid="11" pm="."><plain>5-year survival rates ranged from 53% (95% CI 30--76) (Estonia) to 83% (95% CI 62--94) in France and 83% (95% CI 66--92) in Scotland </plain></SENT>
<SENT sid="12" pm="."><plain>Multivariate analysis show a decreasing HR for the more recent periods of diagnosis from 1 in 1978--1981 to 0.67 (95% CI 0.56--0.79) in 1982--1985 to 0.48 (95% CI 0.40--0.57) in 1986--1989 </plain></SENT>
<SENT sid="13" pm="."><plain>Exploratory analysis, conducted including the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries which provided cases diagnosed until 1992, show a positive trend over time for both types of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>